991 results about "Diagnostic Reagent" patented technology

The invention belongs to the technical field of biological medicines, and particularly relates to application of secretory lactase-like protein (LCTL) as a diagnostic marker in preparation of a diagnostic kit for chronic kidney diseases. According to the present invention, the secretory form of the LCTL is found for the first time, the secretory LCTL content in the human serum is detected by using the existing commercial ELISA kit for the first time, and the further research finds that the secretory LCTL content in the serum of the chronic kidney disease patient is significantly reduced compared with the normal person; and the content of the LCTL in the serum is obviously related to the renal function impairment degree and proteinuria degree of the patient, so that the application of the secretory LCTL in preparing the biomarker for diagnosing the chronic kidney disease is provided for the first time. The invention provides a new method for chronic kidney disease diagnosis, and has important clinical significance and commercial value.

The invention relates to a polypeptide NbG7-4 capable of identifying and neutralizing SFTSV, which comprises three complementary determining regions CDR1-3, and the sequences of the three complementary determining regions CDR1-3 are respectively shown as SEQ ID NO: 1-3. Nanometer antibody drug development and diagnostic kit research and development are carried out on SFTSV which is high in fatality rate but lacks effective vaccines and specific antiviral drugs, the nanometer antibody VHH which is specifically combined with GN is screened through the platform technology of preparing GN protein, inactivating viruses, immunizing alpaca, displaying nanometer monoclonal antibodies through a phage library and the like, the CDR sequence of the nanometer antibody VHH is identified, and the SFTSV with the high fatality rate is obtained. A humanized antibody NbG7-4 is constructed; meanwhile, the curative effect of the NbG7-4 in treating the SFTSV infection is evaluated at the in-vitro cell level. The invention provides a potential nano antibody new drug for clinical treatment of SFTSV, and also provides a corresponding detection kit for diagnosis of SFTSV.

The invention relates to an anti-CK18 monoclonal antibody or an antigen binding fragment thereof, a detection reagent based on the anti-CK18 monoclonal antibody, and a preparation method and application of the anti-CK18 monoclonal antibody or the antigen binding fragment. According to the present invention, the anti-CK18 monoclonal antibody or the antigen binding fragment thereof can specifically bind with the CK18 protein or the fragment thereof with the high affinity, such that the low detection lower limit and the high detection sensitivity can be provided when the anti-CK18 monoclonal antibody or the antigen binding fragment thereof is used for the immunological detection of CK18; therefore, the monoclonal antibody or the antigen binding fragment of the monoclonal antibody has extremely high potential to be developed into an immunodetection antibody or a kit of the CK18 protein, or a diagnostic antibody or a diagnostic kit of diseases (such as NASH) related to abnormality of the CK18 protein (such as abnormal expression level), and has relatively great clinical application prospect and value.

The invention discloses a plasma piRNA combination for early diagnosis of kidney cancer and application, the plasma piRNA combination for early diagnosis of kidney cancer is obtained on the basis of plasma piRNA expression profiles of Chinese population, and a kit for early diagnosis of kidney cancer is established on the basis of the plasma piRNA combination. The kit for early diagnosis of the kidney cancer can accurately predict the onset risk of early diagnosis of the kidney cancer and is beneficial to reduction of the detection cost, meanwhile, the Lasso Logistic regression model is used, the number of variables included in the model is greatly reduced, and application and popularization of the model are facilitated.

The invention provides a recombined protein rSp14-3-3 of sarcocystis tenella, an antibody and an ELISA (Enzyme-Linked Immunosorbent Assay) diagnostic kit of the recombined protein rSp14-3-3 of the sarcocystis tenella. The research firstly provides the recombined protein rSp14-3-3 of the sarcocystis tenella. According to the present invention, the recombinant protein rSp14-3-3 is used as a gene fragment, the obtained gene fragment is connected to an expression vector to carry out induced expression and protein purification, the purified recombinant protein rSp14-3-3 is used to coat an ELISA plate, the ELISA detection method for sheep infected with sarcosporidium is established, and the specific monoclonal antibody for the recombinant protein rSp14-3-3 is further provided. All the products can be applied to diagnosis of infection of sarcocystis in samples, water samples, food, environmental samples and the like, and technical support is provided for subsequent immunological diagnosis of sheep sarcocystis by using the protein.

The invention relates to a nano antibody Nb3-18 capable of identifying and neutralizing SFTSV (swine fever with thrombocytopenia syndrome), which comprises three complementary determining regions CDR1-3, and the sequences of the three complementary determining regions CDR1-3 are respectively shown as SEQ ID NO: 1-3. Nanometer antibody drug development and diagnostic kit research and development are carried out on SFTSV which is high in fatality rate but lacks effective vaccines and specific antiviral drugs, the nanometer antibody VHH which is specifically combined with GN is screened through the platform technology of preparing GN protein, inactivating viruses, immunizing alpaca, displaying nanometer monoclonal antibodies through a phage library and the like, the CDR sequence of the nanometer antibody VHH is identified, and the SFTSV with the high fatality rate is obtained. A humanized antibody Nb3-18 is constructed; meanwhile, the curative effect of Nb3-18 in treating SFTSV infection is evaluated at the in-vitro cell level. The invention provides a potential nano antibody new drug for clinical treatment of SFTSV, and also provides a corresponding detection kit for diagnosis of SFTSV.

The invention provides a chemically modified tetanus toxin C fragment as well as preparation and application thereof. The method for chemically modifying the tetanus toxin C fragment comprises the following steps: 1) reacting the tetanus toxin C fragment with a reducing agent to reduce a disulfide bond in the tetanus toxin C fragment; and 2) carrying out a reaction on the reduced tetanus toxin C fragment and an alkylation reagent, and carrying out modification. The recombinant tetanus toxin C fragment prepared by the method disclosed by the invention not only meets the quality standard required by pharmacopeia, but also has the advantages of stable conformation, high yield, easiness in amplification and low cost, and has a wide application prospect in the preparation of human vaccines, veterinary vaccines and antibody drugs and the development process of in-vitro diagnostic reagents.

The invention belongs to the field of meat pigeon breeding, and particularly relates to miRNAs capable of serving as a trichomonad pigeon biomarker and application of the miRNAs. The invention provides application of miRNAs as a trichomonas pigeonae biomarker in preparation of a trichomonas pigeonae diagnostic reagent. According to the invention, high-throughput sequencing and bioinformatics analysis are simultaneously carried out on oral mucosa small RNA and transcriptome of a trichomonad infected positive individual and a healthy individual for the first time, so that an epigenetic molecular mechanism of oral mucosa tissue of a trichomonad infected regulation body is explained by mining a key significant difference miRNA-mRNA network.

The invention provides application of lactic acid modified histone H3 in preparation of drugs and / or diagnostic kits for preventing and / or treating pancreatic ductal adenocarcinoma, and belongs to the technical field of disease diagnosis and / or treatment. The invention provides application of a lactic acid modified histone H3 as a target spot in preparation of a pancreatic ductal adenocarcinoma diagnostic kit or a medicine for preventing and / or treating pancreatic ductal adenocarcinoma. The site of lactic acid modification is 23-site lysine. The expression of H3K23la detected in clinical sample tissues in pancreatic ductal adenocarcinoma tumor tissues is obviously higher than that in para-carcinoma normal tissues, overexpression and non-expression of H3K23la in cells are regulated and controlled through in-vitro experiments in combination with overexpression and knock-down technologies, and results show that proliferation, invasion and migration capacities of pancreatic ductal adenocarcinoma cells are remarkably inhibited, so that the pancreatic ductal adenocarcinoma cells are remarkably inhibited. Therefore, the H3K23la can be used as a target spot for diagnosis and treatment of the pancreatic duct adenocarcinoma, and has wide application in diagnosis or treatment of the pancreatic duct adenocarcinoma.

The invention discloses preparation and application of a novel diagnostic kit for a mitochondrial network regeneration function evaluation test, and in the invention, combined detection of related proteins DRP1, MFN2, OPA1 and TIM23 is carried out by utilizing four mitochondrial networks, so that the mitochondrial regeneration function state of sample cells is judged. The kit disclosed by the invention is used for detecting samples such as human blood, urine, cell cultures and tissues by utilizing an ELISA (Enzyme-Linked Immunosorbent Assay) method. Results show that the kit can accurately detect the content of four proteins so as to judge the function of sample mitochondria. The mitochondrial network regeneration capacity function evaluation kit based on a double-antibody sandwich method in an ELISA method can conveniently and accurately evaluate the mitochondrial network regeneration capacity in a human body specimen. The invention discloses preparation and application of the novel diagnostic kit for evaluating the regeneration function of the mitochondrial network. The diagnostic kit plays an auxiliary role in mitochondrial detection in scientific research and disease diagnosis and treatment. The method is applied to mitochondrial function evaluation in all diseases with abnormal cell mitochondrial functions.

The invention discloses acinetobacter baumannii and application of the acinetobacter baumannii in construction of a mastitis animal model. The acinetobacter baumannii strain is acinetobacter baumannii AbST3475NMG202308, and the preservation number of the acinetobacter baumannii strain is CGMCC (China General Microbiological Culture Collection Center) No.34450 in the General Microbiological Culture Collection Center of the China Committee for Culture Collection of Microorganisms). Experiments prove that the acinetobacter baumannii has high pathogenicity and can be used for establishing a typical animal model caused by acinetobacter baumannii infection, the animal model can be specifically a mastitis animal model, and a certain technical support is provided for subsequent research and development of drugs or vaccines; the acinetobacter baumannii can also be used for screening antibacterial drugs and developing diagnostic reagents and vaccines. The method has an important application value.

The invention discloses a blood marker for cervical cancer diagnosis and application thereof, and belongs to the field of biomarker detection. The blood marker is a serum exosome tRF-16, and the nucleotide sequence of the serum exosome tRF-16 is as shown in SEQ ID NO. 1. By separating serum exosome RNA of a cervical cancer patient and a healthy control group and combining data of a published database, high-specificity and high-sensitivity tsRNA related to the cervical cancer is found, and the diagnostic kit for clinical detection of the cervical cancer is developed. And simpler, more convenient and quicker help is provided for clinical early screening diagnosis and progress early warning of cervical cancer.

The monoclonal antibody of the glycoprotein Gn of the severe fever with thrombocytopenia syndrome virus is screened on the basis of immune repertoire sequencing, and the biological characteristics of the monoclonal antibody are identified. The method comprises the following steps: taking purified SFTSV-Gn as bait, taking virus specific B cells from an immunized female BALB / c mouse B cell bank, selecting an antibody sequence with potential binding activity by utilizing a 10 * immune repertoire sequencing method in combination with bioinformatics analysis, constructing the antibody sequence to an eukaryotic expression vector pcDNA3.4, expressing and purifying a monoclonal antibody, and identifying the biological activity of the monoclonal antibody. 14 antibodies are selected from 3544 captured B cells, functional verification shows that 12 antibodies can be combined with SFTSV-Gn glycoprotein, and the Gn-5 antibody and the Gn-7 antibody have high combining capacity; western blot, indirect immunofluorescence test and flow cytometry prove that the antibody can specifically recognize the SFTSV, the effective concentration is as low as 2 mu g / mL, and a foundation is laid for development of a rapid diagnosis reagent for the SFTSV.

The invention provides application of a substance for detecting the ratio of lymphocyte subgroups in preparation of a reagent or a kit for diagnosis or auxiliary diagnosis of Graves disease, and belongs to the technical field of preparation of disease diagnosis reagents. A research shows that compared with a healthy sample, the proportion of B cells in a lymphocyte subpopulation of a to-be-detected sample is remarkably increased, the proportion of NK cells is remarkably reduced, the proportion of activated T cells is remarkably reduced, the proportion of memory T cells is remarkably reduced, the proportion of CD4 + memory T cells is remarkably reduced, the proportion of Th1 cells is remarkably reduced, and the proportion of Tc1 cells is remarkably reduced, so that the to-be-detected sample is a GD patient; the substance for detecting the ratio of lymphocyte subgroups is high in sensitivity and specificity when being used for diagnosis or auxiliary diagnosis of Graves disease.

The invention belongs to the field of biological medicine, and relates to an engineered cell membrane nano-vesicle as well as a preparation method and application thereof. The invention provides application of normal fibroblasts in preparation of drugs for treating tumors or tumor diagnostic reagents or nano drug delivery systems or engineered vesicles. The vesicles prepared from the normal fibroblasts have high specificity and capability of rapidly targeting multiple types of tumor tissues, can realize tumor targeted diagnosis imaging or drug delivery, greatly reduce accumulation in normal organs and non-targeted tissues, maximally weaken toxic and side effects of the vesicles in vivo, and have good application prospects. And the safety and the effectiveness are greatly improved.

The invention discloses a novel diagnostic kit for evaluating the autophagy function of a mitochondrial network, which is used for detecting the content of autophagy related proteins NADH, ROMO1, PINK1 and TOM40 of four mitochondrial networks of a human body sample by utilizing an enzyme-linked immunosorbent assay (ELISA) and comprehensively judging the functional state of the mitochondrial of the human body. According to the kit, a microplate reader is used for measuring the absorbance (OD value) of a sample, and the concentration of the sample is calculated through a standard curve. Results show that the kit can accurately detect the content of four proteins, comprehensively judge the mitochondrial network autophagy ability of a human body sample and understand the mitochondrial function state. The kit for diagnosing the mitochondrial function of the double-antibody sandwich method combined with four proteins can conveniently and accurately evaluate the autophagy ability of the mitochondrial network in a human body specimen. The invention discloses preparation of a diagnostic kit for evaluating the autophagy ability of a mitochondrial network. The diagnostic kit can be used for evaluating cell mitochondrial states in cell mitochondrial functions, related disease diagnosis and treatment indexes and scientific research.

The invention belongs to the technical field of biological genetic engineering, and relates to a high-risk myelodysplastic syndrome screening gene and a diagnostic kit thereof. The invention provides an application of detecting YTHDF2, METTL3 and NAT10 gene expression of bone marrow cells of high-risk MDS patients as a specific molecular marker for screening the high-risk myelodysplastic syndrome, and by detecting mRNA expression levels of the YTHDF2, METTL3 and NAT10 genes, the screening of the patients in the high-risk myelodysplastic syndrome is facilitated. Meanwhile, treatment and prognosis evaluation of patients with high-risk myelodysplastic syndromes can be better guided. Only the bone marrow fluid of the patient needs to be extracted and collected during bone marrow cytology examination of the patient, the patient compliance is good, the bone marrow fluid is selected from human bone marrow fluid mononuclear cells, the detection result is more accurate, and the method is suitable for clinical large-scale application.

Provided are a method for diagnosing cancer, a diagnosis kit and compositions useful for measurement of NK cell activity. The incidence of cancer may be diagnosed by monitoring changes in the in vivo immune system through measurement of NK cell activity in blood. Thus, the incidence of cancer may be readily predicted as described herein using a blood sample from a subject.

The invention discloses a monoclonal antibody composition for resisting neurofilament light chain protein and application, the monoclonal antibody composition comprises NfL-Clone 1 and NfL-Clone 2, the amino acid sequence of a heavy chain variable region of the NfL-Clone 1 is as shown in SEQ ID NO.1, and the amino acid sequence of a light chain variable region of the NfL-Clone 1 is as shown in SEQ ID NO.2; the amino acid sequence of a heavy chain variable region of the NfL-Clone 2 is as shown in SEQ ID NO.3, and the amino acid sequence of a light chain variable region of the NfL-Clone 2 is as shown in SEQ ID NO.4. The antibody combination has the characteristics of specificity and high affinity, the NfL can be used as a brain injury biomarker, and meanwhile, the invention also provides a diagnostic detection kit of the antibody for early diagnosis of brain injury of a patient, so that the specificity and sensitivity of a diagnostic reagent are improved.

The invention relates to the technical field of reagent cold-chain transportation monitoring, and particularly discloses a dynamic monitoring and adjusting system for cold-chain transportation of in-vitro diagnostic reagents, which is used for solving the problem that the temperatures of some regions cannot reach or keep a set value in time because local hot spots or cold regions are formed due to non-uniform stacking of the existing in-vitro diagnostic reagents. According to the method, the global temperature data and the reference three-dimensional temperature data in the warehouse are acquired, the first temperature abnormal fluctuation value is calculated, the abnormal deviation between the local temperature data and the global data is automatically identified, the consistency of the temperature data is ensured, the temperature gradient is quantitatively calculated from the global and local angles, and the accuracy of the temperature gradient is improved. Temperature distribution characteristics in the warehouse can be captured in detail, temperature gradient difference values are calculated by comparing different data sources, a reasonable threshold value is set, and automatic early warning is achieved, so that the stability of a temperature control environment is guaranteed, and the quality of an in-vitro diagnostic reagent is protected.

The utility model discloses a novel protein marker diagnostic kit for detecting the muscle injury degree, which comprises a detection kit for detecting the muscle injury degree and a dustproof cover assembled above the detection kit, the detection kit is provided with a detection port for dropping blood of a patient and a display port for displaying a diagnosis result, a reagent card for evaluating the muscle injury degree by detecting the concentration of a specific protein marker in the blood is arranged in the detection kit, and the detection end of the reagent card is located below the detection port. The display end of the reagent card is positioned below the display opening; a positioning opening for positioning the dustproof cover is formed above the detection kit, and a positioning block matched with the positioning opening is arranged in the dustproof cover. According to the utility model, the muscle injury degree of a patient can be detected by quickly reading the novel protein marker in the blood, so that an accurate diagnosis and treatment basis is provided for the treatment of the patient, the detection time of the patient is shortened, and the treatment cost is reduced.

The invention discloses a new application of human YTHDF1, namely an application of a human YTHDF1 gene expression quantity detection reagent in preparation of a prostatic cancer clinical diagnosis reagent. The expression of the human YTHDF1 gene in prostatic cancer tissues and cell lines is increased; after the expression of the YTHDF1 gene is knocked down, the growth of a prostate cancer cell line, the culture of organoids and the growth of transplanted tumors in nude mice are obviously inhibited; according to the present invention, with the application of the RNF7 in the tumor cells, the proliferation of the normal prostate epithelial cells can be promoted by the overexpression, the protein level of the RNF7 in the YTHDF1 knocked-down cells is significantly inhibited, the phenotype of the YTHDF1 knocked-down cells can be rescued by the overexpression of the RNF7, and the sensitivity of the tumor cells to the chemotherapeutic drugs can be promoted by the YTHDF1 knocked-down cells so as to promote the apoptosis; the prostatic cancer can be treated by inhibiting expression drugs of the human YTHDF1 gene, inhibiting expression of the E3 ubiquitin ligase RNF7 gene or screening drugs for degrading the E3 ubiquitin ligase RNF7.

The invention provides a nasopharynx cancer antibody marker and application thereof. Specifically, the invention provides application of the nasopharyngeal carcinoma antibody marker or the detection reagent thereof, the nasopharyngeal carcinoma antibody marker or the detection reagent thereof is used for preparing a diagnostic reagent or a diagnostic kit, and the diagnostic reagent or the diagnostic kit is used for judging the occurrence risk of nasopharyngeal carcinoma. The nasopharyngeal carcinoma antibody marker comprises the following antibody combination: (B) an EBV antibody; (B1) BKRF1-IgA; (B2) BMRF1 (BMRF1-IgA); and (B3) a BALF2-IgA, and (B4) a And (A) an autoantibody comprising any one of the autoantibodies selected from the group consisting of: (A1) anti-TPI1, or a combination thereof; (A2), anti-PRKACA (Pseudomonas And (A3) an anti-TRIM21 (Triglyceride- The nasopharyngeal carcinoma antibody marker can be used as a marker for judging nasopharyngeal carcinoma, and has high sensitivity and specificity.

The invention discloses a related protein marker for assisting early diagnosis of acute myocardial infarction and application of the related protein marker, and is characterized in that the protein marker is at least one of GLRX, CA1, EIF4EBP1, MYL4, SOD1, BOLA2BOLA2B, DDT, TNNI3, GH1, ACY1, POMC, AK1, FABP3, YOD1, GLO1, RANBP1, TGM2, PLPBP, OLR1, CEACAM8, CD2AP, AAMDC and QDPR, and the invention further provides application of the related protein marker in preparation of a reagent or a kit for early diagnosis of myocardial infarction. The kit has the advantages that early-stage AMI diagnosis can be conveniently and quickly realized on the molecular level, the detection efficiency is high, the sensitivity is high, the pertinence is strong, and early-stage discovery and timely treatment of AMI patients are facilitated.

The invention discloses an anti-porcine delta coronavirus S2 subunit monoclonal antibody and a hybridoma cell strain and application thereof, and belongs to the technical field of biological detection. The hybridoma cell strain is preserved in the China Center for Type Culture Collection (CCTCC), and the preservation number is CCTCC NO: C2024223. The hybridoma cell strain can stably secrete a monoclonal antibody for resisting the swine delta coronavirus S2 subunit, the heavy chain of the antibody is IgG2a type, the light chain of the antibody is Kappa type, the epitope of the antibody is 52-NSRC-55, and the epitope is highly conserved in a PDCoV strain. The antibody can specifically recognize PDCoV, has no cross reaction with other common porcine enteroviruses, and can be applied to laboratories and clinical detection. The invention provides a research tool and material for researching the fusion process of the PDCoV and the host cell and developing a PDCoV diagnostic reagent.

The invention relates to a developing embolism microsphere as well as a preparation method and application thereof, and belongs to the technical field of embolism microspheres. The developing embolism microsphere comprises a polymer network structure formed by cross-linking polymerization of an iodine-substituted aminobenzoic acid monomer and a glycidyl ether cross-linking agent with an epoxypropane end group. The developing embolism microsphere provided by the invention has good X-ray developing capability, relatively low density, excellent suspension performance and moderate hardness and elasticity, and can be effectively applied to preparation of tumor radiotherapy, chemotherapy and embolism combined treatment medicines and developing diagnostic reagents.

The invention belongs to the technical field of biological medicines, and discloses a VEGFR-2 affinity peptide and application thereof, the VEGFR-2 affinity peptide can target a vascular endothelial growth factor receptor VEGFR-2, so that the VEGFR-2 affinity peptide can carry out in-vivo diagnosis on tumors with high expression of the VEGFR-2 receptor, and therefore, the VEGFR-2 affinity peptide can be used for in-vivo diagnosis of tumors with high expression of the VEGFR-2 receptor. The VEGFR-2 affinity peptide provided by the invention can be applied to preparation of a novel tumor diagnostic reagent or a novel tumor targeted drug carrier.

The invention provides application of AQP1 protein as a target spot in preparation of a diagnostic reagent and a therapeutic drug for hypoglycaemia nephropathy, and belongs to the technical field of biological medicines.The AQP1 protein is used as the target spot, AQP1 protein expression is reduced by adopting an inhibitor, and the hypoglycaemia nephropathy is obtained. According to the present invention, with the application of the kit, the effects of reducing the renal tubule injury markers in the urine, reducing the glomerular filtration rate or relieving the kidney tissue hypoxia can be achieved, the new idea is provided for the early prevention and treatment of the diabetic nephropathy (DKD), and the early recognition and the effective treatment of the kidney injury of the diabetic patient can be well achieved.

A method for automatically generating a research and development proposal for an in vitro diagnostic kit, performed by a server for automatically generating the research and development proposal, includes: acquiring an initial proposal including intended use information for the kit; providing the acquired initial proposal to a pre-trained language model; acquiring a specification (spec) for the kit from the language model receiving the initial proposal, wherein the acquired specification for the kit includes at least one of a technical specification to be used for the research and development of the kit, a resource specification for the research and development, a design specification for the kit, a regulatory approval specification that is needed to meet for approval, and a performance specification for the kit; and controlling to generate the research and development proposal for the kit including the acquired specification and the intended use information for the kit.

The invention discloses application of Gli1 + interstitial cells or SMOC2 protein thereof in diagnosis, treatment and prognosis evaluation of Crohn disease intestinal stenosis. The invention provides application of Gli1 + interstitial cells and SMOC2 protein as targets in preparation of a diagnostic kit or a therapeutic drug for Crohn disease fibrostenosis, and further provides the diagnostic kit for Crohn disease fibrostenosis and the therapeutic drug for Crohn disease fibrostenosis. Meanwhile, the invention further provides application of the reagent for detecting the expression quantity of the SMOC2 in preparation of the kit for evaluating postoperative recurrence of the Crohn disease fibrostenosis and the corresponding kit for evaluating postoperative recurrence of the Crohn disease fibrostenosis. The invention discusses the effect of the Gli1 + interstitial cells in the attack of intestinal fibrostenosis, evaluates the potential of the Gli1 + interstitial cells as a diagnosis and treatment target, and provides a new thought for the treatment of Crohn disease intestinal stenosis.